Somatropin biosimilar - Bio-Ker

Drug Profile

Somatropin biosimilar - Bio-Ker

Alternative Names: Recombinant somatropin - Bio-Ker

Latest Information Update: 24 Sep 2013

Price : $50

At a glance

  • Originator Bio-Ker
  • Class Growth hormones; Hormonal replacements
  • Mechanism of Action Somatotropin receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Unspecified

Most Recent Events

  • 15 Mar 2016 Biomarkers information updated
  • 11 Sep 2013 Investigation in Undefined indication in Italy (controlled release formulation)
  • 11 Sep 2013 Phase-I clinical trials in Undefined indication in Italy (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top